Acquisition Opportunity – Company in the In Vitro Diagnostics (IVD) Sector

An Italian company with over 30 years’ experience in the in vitro diagnostics (IVD) sector, operating under an integrated business model that combines distribution, research and development, and the manufacture of advanced diagnostic solutions.

The company operates in the biomedical sector with a highly specialised offering that includes:

• the development and manufacture of diagnostic kits
• the distribution of laboratory equipment and solutions
• technical and application support
• research and development activities

Over time, it has built an integrated ecosystem combining scientific expertise, production capacity and commercial presence, creating a distinctive and hard-to-replicate market position.

Revenue of approximately €7.9 million in 2024, with EBITDA of approximately €0.9 million (≈11–12%) and a confirmed growth trend in 2025.

Strengths

• A track record spanning several decades in the biomedical sector
• An integrated model (distribution, R&D and manufacturing)
• Positioning in high value-added niches with barriers to entry
• Technical and scientific expertise and proprietary know-how
• Industry certifications (ISO 13485) and ongoing IVDR compliance
• Established relationships with healthcare operators and the academic network
• Qualified organisational structure and proprietary operational infrastructure
• Balanced economic and financial profile

Investment opportunity

The transaction provides access to a scalable industrial platform operating in a structurally growing sector, with the potential to strengthen market positioning through vertical integration strategies linking distribution and production.

The buyer will be able to further enhance the product portfolio and proprietary expertise, supporting commercial development and international expansion. The initiative also offers the opportunity to generate industrial and commercial synergies and to accelerate growth through targeted investments.

The owners are considering the full sale of the company as part of a process of continuity and value creation, not least given the absence of a direct generational succession.

Confidential negotiations.